Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.
Researcher leads first in-human multiple myeloma study with over 90% response rate
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.